ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,727.79
      0.36%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      Symbol: 
      		Date:
      Sort by:
      DateTimeSourceHeadlineSymbolCompany
      06/01/202411:23AMPR Newswire (Canada)Unifor members begin strike at Gibraltar copper mine
      06/01/202411:00AMPR Newswire (US)ICECO Launches APL35 on Indiegogo - The World's Lightest Aluminum Dual-Zone Freezer
      06/01/202410:34AMPR Newswire (US)The Agency's Agents Named Among Top Producers in the Country by RealTrends + Tom Ferry The Thousand 2024
      06/01/202410:04AMPR Newswire (Canada)Déclaration des ministres Gary Anandasangaree, Patty Hajdu, Dan Vandal et Pascale St-Onge à l'occasion du Mois national de l'histoire autochtone
      06/01/202410:00AMGlobeNewswire Inc.Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)TG:GE9Genmab AS
      06/01/202410:00AMBusiness WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:GMABGenmab AS
      06/01/202410:00AMBusiness Wire"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
      06/01/202410:00AMBusiness WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:BNTXBioNTech SE
      06/01/202410:00AMGlobeNewswire Inc.Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:BNTXBioNTech SE
      06/01/202410:00AMGlobeNewswire Inc.Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem LungenkarzinomXE:22UABioNTech SE
      06/01/202410:00AMGlobeNewswire Inc.Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)TG:22UABioNTech SE
      06/01/202410:00AMGlobeNewswire Inc.Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:BDTXBlack Diamond Therapeutics Inc
      06/01/202410:00AMGlobeNewswire Inc.Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)XE:22UABioNTech SE
      06/01/202410:00AMGlobeNewswire Inc.Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem LungenkarzinomTG:22UABioNTech SE
      06/01/202410:00AMBusiness WireFirst Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
      06/01/202410:00AMPR Newswire (US)Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
      06/01/20249:53AMPR Newswire (Canada)Statement from Ministers Gary Anandasangaree, Patty Hajdu, Dan Vandal, and Pascale St-Onge on National Indigenous History Month
      06/01/20249:30AMBusiness WireTempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
      06/01/20249:30AMPR Newswire (Canada)Message from the Governor General on Pride Month
      06/01/20249:30AMPR Newswire (US)FractIt Revolutionizes Real Estate: Completes Pilot with Tokenization of Luxury Property on Blockchain
      06/01/20249:30AMPR Newswire (Canada)Message de la gouverneure générale à l'occasion du Mois de la fierté
      06/01/20249:15AMBusiness WireオムディアのRANベンダー・レポートでマべニアがトップに輝く
      06/01/20249:14AMGlobeNewswire Inc.Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
      06/01/20249:00AMBusiness WireAnkyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
      06/01/20249:00AMBusiness WireSally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
      06/01/20249:00AMPR Newswire (Canada)Statement by Minister Khera on Italian Heritage Month
      06/01/20249:00AMPR Newswire (US)Vincent Todd Announces the Introduction of Todd Agriscience
      06/01/20249:00AMPR Newswire (US)Beverly Hills MD Celebrates Its 10th Anniversary
      06/01/20249:00AMPR Newswire (Canada)Déclaration de la ministre Khera à l'occasion du Mois du patrimoine italien
      06/01/20249:00AMPR Newswire (US)American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information

      Your Recent History

      LATK
      QTUMETH
      Qtum
      NASDAQ
      ARINNX
      Argus Innovators Model P...
      Delayed Upgrade Clock